CYP 2D6 polymorphism and antipsychotic therapy

Psychiatria Danubina

Volumn 20, Issue 3, 2008, Pages 369-371

  Plesničar, Blanka Kores ^a   Dolžan, Vita ^b   Zalar, Bojan ^c  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c UNIVERSITY PSYCHIATRIC HOSPITAL   (Slovenia)

Author keywords

Antipsychotic; CYP2D6 polymorphism

Indexed keywords

CYTOCHROME P450 2D6; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG METABOLISM; EXTRAPYRAMIDAL SYMPTOM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; OUTPATIENT; PHENOTYPE; POSITIVE AND NEGATIVE SYNDROME SCALE; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SLOVENIA;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CAUSALITY; CYTOCHROME P-450 CYP2D6; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LONG-TERM CARE; LONGITUDINAL STUDIES; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SLOVENIA; TREATMENT OUTCOME;

EID: 54349116470     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Dolžan V, Rudolf Z, Breskvar K. Human CYP2D6 polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis 1995; 16: 2675-8.
2. Vandel P, Haffen E, Vandel S et al. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur J Clin Pharmacol 1999; 55: 659-65.
3. Dawson E, Powell JF, Nothen MM, et al. An association study of debrisoquine hydroxylase (CYP2D6) polymorphism in schizophrenia. Psychiatr Genet 1994; 4: 215-8.
4. Vallada H, Collier D, Dawson E et al. Debrisoquine 4-hydroxylase (CYP2D6) focus and possible susceptibility to schizophrenia. Lancet 1992; 340: 181-2.
5. Hamelin BA, Dorson PG, Pabis D et al. CYP2D6 mutations and therapeutic outcome in schizophrenia patients. Pharmacotherapy 1999; 19: 1057-63.
6. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology 1997; 131: 174-9.
7. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic drug-induced movement disorders in schizophrenia in relation to CYP2D6 genotype. Br J Psychiatry 1997; 170: 23-6.